Chimerix IncNASDAQ:CMRX
- LAST PRICE0.9668
- TODAY'S CHANGE (%)0.0029 (0.3009%)
- Bid / Lots0.9303/ 12
- Ask / Lots0.9800/ 1
- Open / Previous Close0.9740 / 0.9639
- Day Range
- 52 Week Range
- Volume99,188
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CMRX |
|---|---|---|
| 09:32 ET | 3976 | 0.974 |
| 09:38 ET | 300 | 0.9519 |
| 09:41 ET | 11438 | 0.96 |
| 09:45 ET | 10000 | 0.96 |
| 09:48 ET | 3733 | 0.96 |
| 09:52 ET | 200 | 0.97 |
| 09:57 ET | 178 | 0.96 |
| 10:01 ET | 5181 | 0.96 |
| 10:06 ET | 100 | 0.97 |
| 10:10 ET | 300 | 0.965 |
| 10:44 ET | 100 | 0.965 |
| 10:46 ET | 442 | 0.965 |
| 10:48 ET | 103 | 0.9625 |
| 10:50 ET | 100 | 0.965 |
| 10:55 ET | 100 | 0.965 |
| 11:00 ET | 300 | 0.9601 |
| 11:13 ET | 913 | 0.965 |
| 11:20 ET | 500 | 0.962626 |
| 11:24 ET | 240 | 0.9625 |
| 11:26 ET | 300 | 0.965 |
| 11:33 ET | 100 | 0.9688 |
| 11:36 ET | 500 | 0.97 |
| 11:38 ET | 691 | 0.97 |
| 11:40 ET | 214 | 0.97 |
| 11:42 ET | 1163 | 0.96995 |
| 11:44 ET | 300 | 0.97 |
| 11:45 ET | 1509 | 0.97 |
| 11:49 ET | 500 | 0.97 |
| 11:51 ET | 800 | 0.97 |
| 11:54 ET | 1831 | 0.97 |
| 11:56 ET | 100 | 0.9738 |
| 12:02 ET | 200 | 0.9738 |
| 12:36 ET | 200 | 0.9738 |
| 12:57 ET | 100 | 0.9737 |
| 01:15 ET | 1100 | 0.9738 |
| 01:19 ET | 100 | 0.9738 |
| 01:26 ET | 500 | 0.9738 |
| 01:28 ET | 100 | 0.9738 |
| 01:35 ET | 500 | 0.9703 |
| 01:37 ET | 100 | 0.9799 |
| 01:46 ET | 250 | 0.9798 |
| 01:53 ET | 100 | 0.9798 |
| 01:55 ET | 400 | 0.970401 |
| 02:04 ET | 100 | 0.9797 |
| 02:09 ET | 200 | 0.9754 |
| 02:15 ET | 1400 | 0.97275 |
| 02:18 ET | 300 | 0.9741 |
| 02:22 ET | 100 | 0.9741 |
| 02:24 ET | 100 | 0.9754 |
| 02:27 ET | 100 | 0.9741 |
| 02:36 ET | 100 | 0.9701 |
| 02:47 ET | 4270 | 0.9733 |
| 02:49 ET | 3100 | 0.9703 |
| 02:51 ET | 200 | 0.9703 |
| 02:54 ET | 100 | 0.9709 |
| 02:56 ET | 2000 | 0.9711 |
| 02:58 ET | 1100 | 0.975099 |
| 03:00 ET | 300 | 0.9731 |
| 03:02 ET | 448 | 0.971 |
| 03:03 ET | 100 | 0.9752 |
| 03:05 ET | 152 | 0.9731 |
| 03:07 ET | 100 | 0.971 |
| 03:12 ET | 100 | 0.9701 |
| 03:16 ET | 400 | 0.9701 |
| 03:18 ET | 100 | 0.9701 |
| 03:20 ET | 742 | 0.97 |
| 03:21 ET | 100 | 0.9701 |
| 03:25 ET | 5200 | 0.9701 |
| 03:30 ET | 616 | 0.9724 |
| 03:32 ET | 7842 | 0.9724 |
| 03:36 ET | 1000 | 0.9702 |
| 03:38 ET | 1100 | 0.9701 |
| 03:39 ET | 400 | 0.9701 |
| 03:41 ET | 1100 | 0.96771 |
| 03:43 ET | 600 | 0.9656 |
| 03:48 ET | 500 | 0.9656 |
| 03:50 ET | 1000 | 0.9666 |
| 03:52 ET | 1500 | 0.9669 |
| 03:56 ET | 214 | 0.9668 |
| 03:59 ET | 100 | 0.9668 |
May 30, 2024
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference, from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Chimerix Inc | 86.7M | -1.0x | --- |
Allovir Inc | 86.8M | -0.5x | --- |
Relmada Therapeutics Inc | 90.5M | -1.0x | --- |
Genelux Corp | 91.8M | -2.8x | --- |
InflaRx NV | 84.2M | -1.9x | --- |
Sellas Life Sciences Group Inc | 81.4M | -1.3x | --- |
Company Information
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Contact Information
- Headquarters
- 2505 Meridian Parkway, Suite 100DURHAM, NC, United States 27713
- Phone
- 919-806-1074
- Fax
- 919-806-1146
Executives
- Chairman of the Board
- Michael Sherman
- President, Chief Executive Officer, Director
- Michael Andriole
- Chief Financial Officer
- Michelle LaSpaluto
- Chief Operating Officer, Chief Commercial Officer
- Thomas Riga
- Chief Medical Officer
- Allen Melemed
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $86.7M |
|---|---|
Revenue (TTM) | $41.0K |
Shares Outstanding | 89.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-0.93 |
Book Value | $2.17 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 2,113.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -227,407.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
